Kailera grants two 60,000-share option awards
Kailera Therapeutics, Inc. reported that Chief Legal Officer Scott Akamine received two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, as compensation awards.
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. reported that Chief Legal Officer Scott Akamine received two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, as compensation awards.
One 60,000-share option vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 monthly installments, subject to continued service. The second 60,000-share option vests only if the company’s stock reaches at least $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 120,000 shares
Grant/Award
2 txns
Insider
Akamine Scott
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 60,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 120,000 contracts (Direct)
Footnotes (2)
- F1. The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
- F2. The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Key Figures
Time-based option grant size: 60,000 options
Performance-based option grant size: 60,000 options
Exercise price: $16.00 per share
+5 more
8 metrics
Time-based option grant size
60,000 options
Stock option award with time-based vesting
Performance-based option grant size
60,000 options
Stock option award with performance vesting
Exercise price
$16.00 per share
Exercise price for both option grants
Performance stock price hurdle
$40.00 per share
Stock price required for performance option vesting
Time-based initial vesting date
April 16, 2027
25% of time-based options vest on this date
Performance measurement period start
October 16, 2026
Start of performance period for price hurdle
Performance measurement period end
April 16, 2030
End of performance period for price hurdle
Option expiration date
April 16, 2036
Expiration date for both option awards
Key Terms
Stock Option (right to buy), Performance Measurement Period, change in control transaction, vest and become exercisable, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Performance Measurement Period financial
"during the Performance Measurement Period, equals or exceeds $40 per share"
change in control transaction financial
"the stock price in a change in control transaction that occurs during the Performance Measurement Period"
vest and become exercisable financial
"The options vest and become exercisable as to 25% of the underlying shares"
average daily closing price financial
"the average daily closing price of the Company's common stock on Nasdaq"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did KLRA report for Chief Legal Officer Scott Akamine?
Kailera Therapeutics reported that Chief Legal Officer Scott Akamine received two grants of stock options, each for 60,000 shares at a $16.00 exercise price, as compensation awards. These are option grants, not open-market purchases or sales of KLRA common stock.
How do Scott Akamine’s time-based KLRA stock options vest?
The time-based options for 60,000 underlying KLRA shares vest 25% on April 16, 2027, then in 36 substantially equal monthly installments. Vesting requires Mr. Akamine’s continued service with Kailera Therapeutics through each vesting date before the options become exercisable.
What are the performance conditions on KLRA’s performance-based stock options?
The performance-based option grant for 60,000 KLRA shares vests only if the stock’s average daily closing price on Nasdaq equals or exceeds $40 during a 30-day period within the performance measurement window or in a qualifying change in control, subject to continued service.
What is the performance measurement period for KLRA’s performance-based options?
The performance measurement period runs from October 16, 2026 through April 16, 2030. During this time, vesting can occur if Kailera Therapeutics’ common stock meets the $40 average closing price hurdle or achieves that price in a qualifying change in control transaction.
When do Scott Akamine’s KLRA stock options expire if unexercised?
Both stock option grants reported for Scott Akamine have an expiration date of April 16, 2036. After that date, any unexercised options will no longer be exercisable, even if they previously vested based on time or performance conditions.
Are Scott Akamine’s reported KLRA transactions open-market buys or sells?
No. The Form 4 shows code "A" transactions, which are grants or awards of derivative securities. These represent stock option grants from Kailera Therapeutics at a $16.00 exercise price, not open-market purchases or sales of existing KLRA common shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
